Status:
COMPLETED
AESOPS Trial 2 (AESOPS-2): Availability of Opioid Harm
Lead Sponsor:
University of Southern California
Collaborating Sponsors:
Northwestern University
AltaMed Health Services Corporation
Conditions:
Opioid Abuse
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The opioid epidemic is the largest man-made public health crisis the United States has faced. The objective of Trial 2 of the Application of Economics \& Social psychology to improve Opioid Prescribin...
Detailed Description
In AESOPS-2, a multi-site study, random assignment determines if prescribers to persons who suffer an opioid overdose (fatal or nonfatal) learn of this event (intervention) or practice usual-care (con...
Eligibility Criteria
Inclusion
- 1\) The clinician prescribed a qualifying scheduled drug to a patient in the 12 months prior to their non-fatal or fatal overdose 2) the patient is 18 years old or older at the time of the overdose, 3) the provider practices within a health system enrolled in the study, and 4) the overdose occurs during the 12-month observation period. Qualifying prescriptions include those for one of the following scheduled drugs: opioids, benzodiazepines, muscle relaxants or sedative-hypnotics.
Exclusion
- Prescriptions to patients in hospice or with active cancer
Key Trial Info
Start Date :
January 23 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 18 2024
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT04758637
Start Date
January 23 2023
End Date
March 18 2024
Last Update
October 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University
Chicago, Illinois, United States, 60611